ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
PROK 10.14.2024
WINSTON-SALEM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) --ProKidney Corp. (Nasdaq: PROK)(“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present five posters, including one late-breaking clinical trial, at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held on October 23-27, 2024, in San Diego, CA.
The titles for the accepted abstracts are provided below and accessible online at:https://www.asn-online.org/education/kidneyweek/2024/program-search-abstract.aspx
Late-Breaking Poster Presentation
Rilparencel Autologous Cell Therapy in Patients with Diabetes and Advanced CKD: Phase 2 Interim ResultsSession Title: Late-Breaking Clinical Trials PostersSession Date & Time: October 24, 2024, from 10:00 AM to 12:00 PM PDTPoster Board #: TH-PO1177
Poster Presentations
Phase 3 Clinical Trial Candidate Rilparencel Demonstrates Consistent Phenotypic Characteristics During Ex Vivo Culture Expansion ProcessSession Title: Development, Organoids, Injury, and RegenerationSession Date, Time: October 24, 2024, from 10:00 AM to 12:00 PM PDTPoster Board #: TH-PO415
Phase 3 Clinical Candidate Rilparencel Demonstrates Weak Association with Renal Epithelial Senescence-Associated Secretory PhenotypeSession Title: CKD: Kidney Function and Extrarenal ComplicationsSession Date, Time: October 25, 2024, from 10:00 AM to 12:00 PM PDTPoster Board #: FR-PO1156
Late Clinical-stage Candidate Rilparencel’s Effect on Kidney Function and Biological Pathways in a Type 2 Diabetes and CKD Patient SubsetSession Title: Diabetic Kidney Disease: Basic - 2Session Date, Time: October 26, 2024, from 10:00 AM to 12:00 PM PDTPoster Board #: SA-PO263
Phase 3 Clinical Candidate Rilparencel Demonstrates Distinct Secretomic Signatures at Key Points in Manufacturing, Suggesting a Reduced Inflammatory and Fibrotic ProfileSession Title: Diabetic Kidney Disease: Basic - 2Session Date, Time: October 26, 2024, from 10:00 AM to 12:00 PM PDTPoster Board #: SA-PO287
Following the event, a copy of the poster presentations will be available on the Company’s website at:https://prokidney.com/our-technology/publications/
Additional information on ASN Kidney Week 2024 can be accessed online at:https://www.asn-online.org/education/kidneyweek
About ProKidneyProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-of-its-kind, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visitwww.prokidney.com.
Investor Contacts:
ProKidneyEthan HoldawayEthan.Holdaway@prokidney.com
LifeSci Advisors, LLCDaniel FerryDaniel@lifesciadvisors.com
